116 related articles for article (PubMed ID: 1417088)
1. Influence on erythropoietin levels of treatment with cisplatinum-endoxan.
Lechner W; Artner-Dworzak E; Sölder E; Sachsenmaier M; Kölle D; Moncayo H; Reitsamer R
Arch Gynecol Obstet; 1992; 252(1):49-53. PubMed ID: 1417088
[TBL] [Abstract][Full Text] [Related]
2. Serum erythropoietin levels in gynecologic cancer patients during cisplatin combination chemotherapy.
Hasegawa I; Tanaka K
Gynecol Oncol; 1992 Jul; 46(1):65-8. PubMed ID: 1634143
[TBL] [Abstract][Full Text] [Related]
3. [Magnesium deficiency caused by epirubicin/cisplatin].
Lechner W; Söldner E; Sachsenmaier M; Philadelphy H; Jarosch E
Zentralbl Gynakol; 1989; 111(21):1438-40. PubMed ID: 2603585
[TBL] [Abstract][Full Text] [Related]
4. Chemotherapy for gynecologic malignancies at Siriraj Hospital, Bangkok.
Senapad S
Southeast Asian J Trop Med Public Health; 1985 Dec; 16(4):656-9. PubMed ID: 3939044
[No Abstract] [Full Text] [Related]
5. The effects of chemotherapy including cisplatin on vitamin D metabolism.
Gao Y; Shimizu M; Yamada S; Ozaki Y; Aso T
Endocr J; 1993 Dec; 40(6):737-42. PubMed ID: 7951544
[TBL] [Abstract][Full Text] [Related]
6. [Evaluation of cardiotoxicity by radionuclide angiocardiography in the chemotherapy of gynecologic malignancies].
Yabuta M
Nihon Gan Chiryo Gakkai Shi; 1990 Jun; 25(6):1146-56. PubMed ID: 2398300
[TBL] [Abstract][Full Text] [Related]
7. [Combination chemotherapy with methotrexate (MTX), vincristine (VCR), cisplatinum (CDDP), cyclophosphamide (CPM), adriamycin (ADM), and bleomycin (BLM); MVP-CAB in patients with advanced urothelial tract cancer].
Fujii A; Morishita S; Nakamura I; Oka Y; Ohshima H; Nagata H; Iwamoto T; Izumi T; Miyasaki Z; Ito N
Nihon Hinyokika Gakkai Zasshi; 1988 Jun; 79(6):985-93. PubMed ID: 2460657
[No Abstract] [Full Text] [Related]
8. Increased nephrotoxicity of combination taxol and cisplatin chemotherapy in gynecologic cancers as compared to cisplatin alone.
Merouani A; Davidson SA; Schrier RW
Am J Nephrol; 1997; 17(1):53-8. PubMed ID: 9057954
[TBL] [Abstract][Full Text] [Related]
9. [Ambulatory use of cisplatin. Preliminary considerations].
de Oliveira Filho JA; da Cunha FM
Rev Paul Med; 1983; 101(5):199-202. PubMed ID: 6200911
[No Abstract] [Full Text] [Related]
10. Estimation of cardiotoxicity of epirubicin-cisplatin by determination of myoglobin.
Lechner W; Reider W; Hetzel H; Daxenbichler G; Marth C
Gynecol Obstet Invest; 1986; 22(1):42-6. PubMed ID: 3462098
[TBL] [Abstract][Full Text] [Related]
11. [Bone marrow suppression in gynecological patients with malignant tumor treated with combination chemotherapy cyclophosphamide, pirarubicin and cisplatin].
Kozaki S; Yanagawa Y; Ueki M; Sugimoto O; Okazaki T; Saeki M; Nomura H; Kanda T; Iwai E; Miyawaki Y
Gan To Kagaku Ryoho; 1990 Jun; 17(6):1189-93. PubMed ID: 2350194
[TBL] [Abstract][Full Text] [Related]
12. Paclitaxel delivered as a 3-hr infusion with cisplatin in patients with gynecologic cancers: unexpected incidence of neurotoxicity.
Connelly E; Markman M; Kennedy A; Webster K; Kulp B; Peterson G; Belinson J
Gynecol Oncol; 1996 Aug; 62(2):166-8. PubMed ID: 8751544
[TBL] [Abstract][Full Text] [Related]
13. Comparison of oral versus intravenous ramosetron in prevention of acute cisplatin-induced emesis: a randomized controlled trial.
Tantipalakorn C; Srisomboon J; Thienthong H; Pantusart A; Suprasert P; Saereesongkhun C; Eamtang S; Sutthichat A; Pautad N
J Med Assoc Thai; 2004 Feb; 87(2):119-25. PubMed ID: 15061293
[TBL] [Abstract][Full Text] [Related]
14. Domiciliary chemotherapy for malignant disease.
Malone J; Kavanagh J; Crosson K; Streckfuss B
Eur J Gynaecol Oncol; 1986; 7(2):120-1. PubMed ID: 3720782
[TBL] [Abstract][Full Text] [Related]
15. [Kampo therapy for side effects of gynecologic carcinomatous chemotherapy].
Fushiki H
Nihon Rinsho; 2004 Oct; 62 Suppl 10():623-6. PubMed ID: 15535320
[No Abstract] [Full Text] [Related]
16. [Consecutive intra-arterial infusion of cis-diamminedichloroplatinum with continuous intra-arterial infusion of 5-fluorouracil in patients with advanced gynecologic cancer].
Shimizu Y; Miura S; Okudaira Y
Nihon Gan Chiryo Gakkai Shi; 1986 Apr; 21(3):655-63. PubMed ID: 3734536
[No Abstract] [Full Text] [Related]
17. Chemotherapy consisting of cisplatin, epirubicin, and cyclophosphamide in advanced ovarian carcinoma. The Gynecologic Oncology Group of the Comprehensive Cancer Center, Limburg, The Netherlands.
Stoot J; Wils J; von Geuns H; Smeets J; Schouten L
Cancer Invest; 1993; 11(1):1-5. PubMed ID: 8422593
[TBL] [Abstract][Full Text] [Related]
18. [Use of metoclopramide and dexamethasone in preventing vomiting associated with antineoplastic chemotherapy].
Sobkowski W; Jassem J
Pol Tyg Lek; 1987 Jul 6-7; 42(27-28):841-3. PubMed ID: 3684761
[No Abstract] [Full Text] [Related]
19. Phase I trial of escalating doses of paclitaxel combined with fixed doses of cisplatin and doxorubicin in advanced endometrial cancer and other gynecologic malignancies: a Gynecologic Oncology Group study.
Fleming GF; Fowler JM; Waggoner SE; Copeland LJ; Greer BE; Horowitz I; Sutton G; Schilder RJ; Fracasso PM; Ball HG; McGuire WP
J Clin Oncol; 2001 Feb; 19(4):1021-9. PubMed ID: 11181665
[TBL] [Abstract][Full Text] [Related]
20. Gynecologic cancer treated with a chemotherapy regimen containing cisplatin.
Wheelock JB
Gynecol Oncol; 1989 Mar; 32(3):401. PubMed ID: 2920965
[No Abstract] [Full Text] [Related]
[Next] [New Search]
